VIDEO: Takeaways from AHA 2022 with B. Hadley Wilson, MD, FACC
Click Here to Manage Email Alerts
CHICAGO — In this Healio exclusive, B. Hadley Wilson, MD, FACC, provides his perspective on several late-breaking clinical trials presented at the American Heart Association Scientific Sessions.
Wilson discusses results of OPTION, a randomized, open-label, noninferiority trial that evaluated efficacy and safety of indobufen compared with aspirin after coronary drug-eluting stent implantation; BRIGHT-4, a randomized trial that assessed high-dose bivalirudin infusion after percutaneous coronary intervention compared with heparin in STEMI; ECMO-CS, a randomized trial that looked at early extracorporeal membrane oxygenation compared with a conservative strategy for the treatment of cardiogenic shock; and ISCHEMIA-EXTENDed, an extended follow-up study of 4,825 patients from the ISCHEMIA trial.
Wilson is executive vice chair of Atrium Health’s Sanger Heart & Vascular Institute, clinical professor of medicine at UNC School of Medicine and vice president of the American College of Cardiology.
Watch the video for more.
Collapse
Healio Interviews
Click Here to Manage Email Alerts